Abstract: The invention releates to a polypeptide of formula IR.sup.1 --CO--A.sup.1 --A.sup.2 --A.sup.3 A.sup.3 --A.sup.4 --A.sup.5 --A.sup.6 --Qwherein each of the generic terms is disclosed in full in the specification and includesR.sup.1 is a 5- or 6-membered unsaturated heterocyclic ring which contains one, two or three nitrogen atoms, which ring may optionally bear one or two substituents; a.sup.1 is a direct link to A.sup.2 ; or is His or D-His; A.sup.2 is Trp or MeTrp; A.sup.3 is Ala or MeAla; A.sup.4 is Val; A.sup.5 is Gly or D-Ala; A.sup.6 is His or Lys(Z); and Q is a group of the formula --A.sup.7.R.sup.2 in which A.sup.7 is Leu or LeMeu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino.The compounds possess antagonist properties against bombesin-like peptides and are of value in treatment of malignant disease in warm-blooded animals.

Abstract: The invention relates to a polypeptide of formula I:R.sup.1 -A.sup.1 -A.sup.2 -A.sup.3 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.9 -Qwherein each of the generic terms is disclosed in full in the specification and includes: R.sup.1 is (2-6C)alkanoyl or (1-4C)alkoxycarbonyl; A.sup.1 is a direct link to A.sup.2, or is Gly or Arg; A.sup.2 is a direct link to A.sup.3, or is Gly or Pro; A.sup.3 is a direct link to A.sup.4, or is Lys or Lys(Z); A.sup.4 is His or D-His; A.sup.5 is Trp or MeTrp; A.sup.6 is Ala or MeAla; A.sup.7 is Val or MeVal; A.sup.8 is Gly or Sar; A.sup.9 is His or MeHis; and Q is a group of the formula -A.sup.10.R.sup.2 in which A.sup.10 is Leu or D-Leu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino; provided that when R.sup.1 is acetyl and -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9 -Q is -His-Trp-Ala-Val-Gly-His-Leu-NH.sub.2 then -A.sup.1 -A.sup.2 -A.sup.3 - is not a direct link to His.

Abstract: Proline derivatives of the formulae: ##STR1## wherein R.sup.1 through R.sup.11 have defined values, and acid- and base-addition salts thereof, and equilibrium addition compounds of the aldehyde group thereof; processes for their preparation; pharmaceutical compositions; and intermediates for preparing said proline derivatives. The proline derivatives are human leukocyte elastase inhibitors which are useful, for example, in treating pulmonary emphysema.

Abstract: Proline derivatives of the formulae: ##STR1## wherein R.sup.1 through R.sup.11 have defined values, and acid- and base-addition salts thereof, and equilibrium addition compounds of the aldehyde group thereof; processes for their preparation; pharmaceutical compositions; and intermediates for preparing said proline derivatives. The proline derivatives are human leukocyte elastase inhibitors which are useful, for example, in treating pulmonary emphysema.

Abstract: The disclosure relates to novel polypeptides which possess analgesic activity, to processes for their manufacture and to pharmaceutical compositions containing them.

Abstract: The disclosure relates to novel polypeptides which are analogues of luliberin and which possess luliberin antagonist activity, to processes for their manufacture and to compositions containing them. Typical of the polypeptides disclosed is ##STR1## in which A is D-Phe, D-Trp or a direct bond.

Abstract: The disclosure relates to novel polypeptides which possess analgesic and sedative activity, to processes for their manufacture and to compositions containing them. Typical of the peptides disclosed isH-Tyr-D-Ala-Gly-Phe-Leu-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-OH.